A new peer-reviewed study published recently has sparked alarm regarding the connection between Pfizer's mRNA COVID-19 vaccine and the occurrence of a rare but severe eye disorder, superior limbic keratoconjunctivitis (SLK). In an article published in the Cureus peer-reviewed medical journal, researchers highlighted an emerging trend of eye inflammation and malfunction after COVID-19 vaccination, more so among those with pre-existing autoimmune conditions.

Although the general risk seems to be low, the study emphasizes the significance of post-vaccine surveillance and the need for physicians and ophthalmologists to take recent vaccination status into account when diagnosing unexplained eye symptoms. Pfizer remains silent about the findings of cases.

Also Read: Egg Recall California 2025: How to Protect Yourself Amid Salmonella Cases

Researchers at a Turkish medical institution analyzed 64 individuals—128 eyes—before and after they received both doses of the Pfizer-BioNTech COVID-19 vaccine. Two months after the second dose, the researchers documented measurable changes in the cornea’s endothelium, the innermost layer that plays a critical role in maintaining corneal clarity. Significant changes noted were:

• Thickening of the cornea from a mean of 528 to 542 micrometers
• An 8% reduction in endothelial cells from 2,597 to 2,378 cells/mm²
• A 2% reduction in healthy hexagon-shaped cells
• Greater variation in cell size, which may indicate cellular stress or damage

Although the study had no immediate detection of visual impairment among the participants, the scientists observed these changes as possible harbingers of long-term dysfunction, particularly among individuals with pre-existing eye problems.

Why Is the Corneal Endothelium Important?

The endothelium is a single-cell layer responsible for pumping excess fluid out of the cornea to keep it transparent. Unlike most other cells in the body, these cells don’t regenerate. Once they’re damaged, the surrounding cells stretch to fill the gaps—leading to irregularity in cell shape and size, which was observed in this study. A low cell count or disorganized endothelial layer can result in conditions like:

Corneal edema: Swelling that causes blurred or hazy vision

Bullous keratopathy: Painful blisters on the eye surface

Corneal decompensation: Permanent loss of clarity, potentially requiring a transplant

While healthy adults can often tolerate mild changes, individuals with already low endothelial cell counts, due to aging, Fuchs’ dystrophy, prior surgeries, or eye trauma—could be more vulnerable.

Also Read: 'RFK Is Weaponizing Public Health': White House Sacks US CDC Director Susan Monarez Amid Vaccine Cuts

Researchers emphasized that these effects could be temporary, and long-term follow-up is essential to determine whether the changes persist or resolve on their own. They advised individuals with low endothelial counts or past corneal grafts to undergo more frequent checkups following vaccination, including specular microscopy, a non-invasive scan that measures endothelial health.

What We Know About Vaccine's Side Effects

The findings contribute to a broader conversation around vaccine safety, particularly concerning rare but notable adverse effects. In 2021, U.S. regulators added myocarditis and pericarditis warnings to the Pfizer and Moderna vaccines, mostly affecting men aged 16 to 25.

While such side effects remain rare, increased transparency and post-market surveillance have become crucial for maintaining public trust. The Turkish corneal study does not accuse Pfizer of negligence, nor does it dispute the vaccine's life-saving role during the pandemic. However, it adds new dimensions to ongoing risk-benefit assessments, especially for individuals with specific medical histories.

Should You Be Worried?

For most people, especially those without underlying eye conditions, the reported corneal changes likely have little or no practical impact. The measured drop in endothelial cells still kept participants well within the healthy range (above 2,000 cells/mm²).

But if you’ve had previous eye surgery, a corneal transplant, or conditions like Fuchs' dystrophy, it’s worth discussing this study with your ophthalmologist. You may be advised to monitor corneal health pre- and post-vaccination.

Also, while the study used robust diagnostic tools—like Sirius corneal topography and the Tomey EM-4000 specular microscope—the sample size of 64 participants is small. Larger, multicenter studies will be essential to confirm and further interpret the findings.

The researchers made it clear that they are not advising against vaccination. Instead, they are calling for more expansive, longitudinal studies to investigate whether these changes persist, worsen, or reverse over time.

Their key recommendation: monitor individuals who are already at elevated ophthalmic risk. If changes continue to be found months or years after vaccination, guidelines may need adjusting—not to limit vaccination, but to ensure it’s done as safely as possible for all populations.

In the meantime, healthcare providers may consider integrating corneal health screenings into vaccination protocols for high-risk individuals, just as cardiology screenings were emphasized after early reports of vaccine-linked myocarditis.

The Pfizer COVID-19 vaccine remains a vital tool in global health, but emerging research like this adds nuance to the story. The Turkish study’s findings are not a cause for panic, but they are a signal for further investigation, especially in populations with vulnerable eye health.

The COVID-19 pandemic showed how science evolves in real-time—and this study is another chapter in that unfolding story. As always, the best course of action is informed dialogue between patients and healthcare professionals.

If you have a history of eye disease or corneal surgery, consider scheduling an eye exam before and after vaccination—and don’t skip follow-ups. Your vision is worth the extra look.

A deadly meningitis outbreak in Kent has claimed two young lives and left several others seriously ill, prompting health authorities to urgently warn students and young people in the area.

According to reports, the outbreak involves invasive meningitis, a severe infection that spreads quickly and can become life threatening within hours. One of the victims was a student at the University of Kent, while the other was a Year 13 pupil from Faversham. Most of the affected individuals are between 18 and 21 years old, and several are university students.

Health officials say at least 11 people from the Canterbury area have been hospitalized and are currently receiving treatment.

The UK Health Security Agency (UKHSA) has begun contacting more than 30,000 students, staff members, and their families to inform them about the outbreak and the precautions being taken.

Read: Meningitis Outbreak: University of Kent Student Among Two Who Died of the ‘Invasive’ Disease

Strain B Identified As The Cause

Government scientists have now confirmed that the outbreak is caused by meningococcal strain B, a type of bacteria that many young people have not been vaccinated against.

Gayatri Amirthalingam, deputy director of immunization and vaccine preventable diseases at the UKHSA, said laboratory testing identified the strain responsible for the cluster of infections.

She explained that teenagers in the UK usually receive a meningococcal vaccine around the age of 13 or 14, but that vaccine protects against strains A, C, W, and Y, not strain B.

This means many teenagers and young adults remain vulnerable unless they received the meningitis B vaccine privately.

Why Many Young People Are Not Vaccinated

The meningitis B vaccine was introduced into the UK’s National Health Service routine immunization schedule for babies in 2015.

As a result, people born before 2015 would not have received the vaccine through the public programme. Some may have chosen to get it privately, but many did not.

Private vaccination can cost between £100 and £120 per dose in the UK, and a full course generally requires two doses.

Experts say this gap in vaccination coverage may partly explain why university-age students are susceptible during outbreaks.

Antibiotics Being Offered As Preventive Measure

Health authorities are urging anyone who may have been exposed to the infection to take preventive antibiotics immediately. UKHSA has specifically advised people who visited Club Chemistry in Canterbury between 5 and 7 March to come forward for antibiotic treatment as a precaution.

Officials say taking antibiotics quickly can help stop the bacteria from developing into disease and also prevent it from spreading to others. Amirthalingam reassured students that those who have received antibiotics can safely travel home and be around family members.

Can Sharing Vapes Spread The Infection?

The disease spreads mainly through close contact, including activities where saliva is shared. Amirthalingam noted that sharing vapes can be one possible route of transmission, although it is not the only one.

Experts say anything that goes into the mouth, including drinks, cigarettes, or vapes, can potentially pass bacteria from one person to another.

Because meningococcal bacteria can live in the throat and nose, close social contact among students often increases the risk during outbreaks.

What Is Meningitis?

Meningitis is an infection that causes inflammation of the meninges, the protective membranes surrounding the brain and spinal cord.

The illness is most often caused by bacterial or viral infections, although fungal and other causes are also possible.

Symptoms can include fever, headache, stiff neck, confusion, and sensitivity to light. In severe cases, bacterial meningitis can lead to hearing loss, neurological complications, or death if treatment is delayed.

Doctors stress that early recognition and immediate medical care are critical because the condition can worsen rapidly within a few hours.

"God asks no man whether he will accept life. That is not the choice. You must take it. The only choice is how."

This is what Justice JB Pardiwala said, quoting Henry Ward Beecher to allow India's first ever passive euthanasia for Harish Rana. AIIMS Delhi has now started protocols to implement the Supreme Court verdict for Harish Rana's passive euthanasia. Sources and several reports have mentioned that the process could take two to three weeks.

How Is AIIMS Delhi Preparing For Passive Euthanasia?

A specialized team headed by professor and head of the department of anesthesia and palliative medicine, Dr Seema Mishra, has been constituted to implement the process. The team comprises doctors from departments of neurosurgery, onco-anesthesia, and palliative medicine, and psychiatry.

“The process generally involves withholding or withdrawing the nutritional support gradually while ensuring adequate pain relief. The patient is given palliative sedation so that he or she is not in distress. Life support measures such as artificial nutrition, oxygen and medications are slowly withdrawn. The aim is not to prolong nor hasten death,” Dr Sushma Bhatnagar, former head of the department of onco-anaesthesia, pain and palliative care, AIIMS-Delhi.

Harish Rana Update

A video from Rana's home in Ghaziabad showed that relatives were offering prayers and a member of the Brahma Kumaris put a 'tilak' on his forehead. She said, "Sabko maaf karte hue, sabse maafi mange hue, so jaao...theek hai." Which loosely translates to: Forgiving everyone and asking forgiveness from everyone. Now sleep. It's okay.

The Brahma Kumari seen in the video was Sister Lovely from Mohan Nagar Seva Kendra in Ghaziabad. Komal, who is also a member of Brahma Kumaris based in Mount Abu, told this to news agency Press Trust of India (PTI). "She is following a ritual with the words that mean he (Harish) leave the world in a happy state, seeking and giving forgiveness...it is part of a meditative chant that comforts the soul and eases the entire process of soul merging with the sublime," she told PTI.

According to Komal, alongside medical consultations, the family also sought spiritual guidance as they prepared for the inevitable after the Supreme Court’s directions.

Read: Harish Rana Case Brings Spotlight On How Passive Euthanasia Has Evolved Over The Years

Harish Rana's Passive Euthanasia

The Supreme Court of India, in a landmark judgment allowed 32-year-old Harish Rana, who had been living in a vegetative state for last 13 years, the right to die. This means, that the apex court allowed passive euthanasia for Rana. The bench comprising Justice JB Pardiwala an Justice KV Vishwanathan allowed the withdrawal of life support of Rana, who has been in a coma and kept alive on tubes for breathing and nutrition after he sustained severe head injuries following a fall from a building in 2013 in Chandigarh.

The judgment is a win, however, Ashok, Rana's father said that his feelings are mixed. "As a father, this is extremely painful. But on humanitarian grounds, this is the best we can do for my son." He continued, "It is just not a matter of my son, but there are many others in such a state in the country. I think it is the grace of God who guided the Supreme Court judges... I am happy that with this judgments, many others may find a way."

Tech giant Microsoft's new artificial intelligence model GigaTIME will help reduce time and cost as well as expand access to cancer care, said CEO Satya Nadella today.

Nadella noted that its multimodal AI system has shown promise in transforming routine pathology slides into detailed spatial proteomics data -- a high-resolution map of proteins.

The advanced technology may help doctors analyze tumors faster, thus bringing hope to millions of cancer patients worldwide for a better and faster diagnosis.

Taking to social media platform X, Nadella said: “We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care”.

What is GigaTIME

GigaTIME is a multimodal AI model for translating routinely available hematoxylin and eosin (H&E) pathology slides to virtual multiplex immunofluorescence (mIF) images.

H&E is the "gold standard" technique in pathology for diagnosing cancer. The mIF images share details of proteins and their locations in cancer cells, thus advancing precision immuno-oncology research.

Developed in collaboration with Providence and the University of Washington, the team trained GigaTIME on a dataset of 40 million cells with paired H&E and mIF images across 21 protein channels.

The multimodal AI, which analyzed standard pathology slides, showed the potential to generate a “virtual population” of tumor cells. It also revealed the detailed protein activity within cancer cells.

The images also offer deeper insights into how tumors behave and disease progression, enabling doctors to cut down the time and cost of diagnosis.

“GigaTIME is about unlocking insights that were previously out of reach,” explained Carlo Bifulco, chief medical officer of Providence Genomics and medical director of cancer genomics and precision oncology at the Providence Cancer Institute, in a Microsoft Blogpost

“By analyzing the tumor microenvironment of thousands of patients, GigaTIME has the potential to accelerate discoveries that will shape the future of precision oncology and improve patient outcomes,” Bifulco added.

How GigaTIME Works

In the paper, detailed in the journal Cell, scientists from Microsoft reported that they applied GigaTIME to 14,256 cancer patients from 51 hospitals and over a thousand clinics.

The AI system generated a virtual population of around 300,000 mIF images spanning 24 cancer types and 306 cancer subtypes.

This virtual population uncovered 1,234 statistically significant associations linking mIF protein activations with key clinical attributes such as biomarkers, staging, and patient survival.

"By translating readily available H&E pathology slides into high-resolution virtual mIF data, GigaTIME provides a novel research framework for exploring precision immuno-oncology through population-scale TIME analysis and discovery," the researchers said.

"The GigaTIME model is publicly available to help accelerate clinical research in precision oncology," they added.